Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + trastuzumab + paclitaxel in HER2-positive metastatic breast cancer
NL-OMON35692Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus, trastuzumab and paclitaxel in breast cancer, sponsored by Novartis. Primary endpoint: Overall response rate. Started Mar 2009; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON35692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35692.